Circulating tumor cells as a potential efficacy end point in clinical trials of hormone-resistant prostate cancer
- PMID: 19116088
- DOI: 10.1007/s11934-009-0002-2
Circulating tumor cells as a potential efficacy end point in clinical trials of hormone-resistant prostate cancer
Comment on
-
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.Clin Cancer Res. 2008 Oct 1;14(19):6302-9. doi: 10.1158/1078-0432.CCR-08-0872. Clin Cancer Res. 2008. PMID: 18829513